Femasys (NASDAQ:FEMY) Stock Price Down 2.4% – Time to Sell?

by · The Markets Daily

Femasys Inc. (NASDAQ:FEMY – Get Free Report) shares were down 2.4% on Monday . The company traded as low as $0.3610 and last traded at $0.3779. Approximately 837,438 shares were traded during trading, a decline of 59% from the average daily volume of 2,021,601 shares. The stock had previously closed at $0.3870.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on FEMY shares. Lake Street Capital started coverage on shares of Femasys in a research note on Tuesday, March 3rd. They set a “buy” rating and a $1.50 target price on the stock. Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 18th. Finally, Wall Street Zen lowered shares of Femasys from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.33.

Get Our Latest Analysis on Femasys

Femasys Price Performance

The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $22.82 million, a PE ratio of -1.40 and a beta of -2.23. The firm’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.58.

Femasys (NASDAQ:FEMY – Get Free Report) last issued its earnings results on Friday, May 8th. The company reported $0.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.07. The business had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.77 million. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%.

Hedge Funds Weigh In On Femasys

Hedge funds have recently modified their holdings of the company. Kovack Advisors Inc. bought a new position in shares of Femasys in the fourth quarter worth approximately $27,000. HRT Financial LP bought a new position in shares of Femasys in the fourth quarter worth approximately $30,000. State Street Corp boosted its position in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the period. Jane Street Group LLC bought a new position in shares of Femasys in the fourth quarter worth approximately $62,000. Finally, Banco BTG Pactual S.A. bought a new position in shares of Femasys in the fourth quarter worth approximately $88,000. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

(Get Free Report)

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.

See Also